Remove ACE Inhibitor Remove Heart Failure Remove Kidney Disease
article thumbnail

Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry

Open Heart

Introduction Heart failure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Frailty, chronic kidney disease and ischaemic heart disease increased significantly versus the first period (p<0.001). Treatment is complicated by side effects and comorbidities.

article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

article thumbnail

Understanding the failings of yesterday to improve the outcomes of tomorrow: a CardioRenal story

The British Journal of Cardiology

2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”